RecruitingNot ApplicableNCT07144527

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Sponsor

Scott Silveira

Enrollment

40 participants

Start Date

Feb 21, 2026

Study Type

INTERVENTIONAL

Conditions

Frailty Aging Exercise Tolerance Healthy Male and Female Subjects

Summary

This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.

Eligibility

Min Age: 60 YearsMax Age: 80 Years

Inclusion Criteria11

Adults aged 60 to 80 years, of any sex
Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing
Montreal Cognitive Assessment (MoCA) score of 26 or higher
Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation
Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling
Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications
Ability to attend at least four in-person laboratory visits in Beverly Hills, California
Non-smoker for at least 12 months
Able to provide informed consent and comply with study procedures
Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study

Exclusion Criteria12

Severe cardiovascular disease (e.g., recent myocardial infarction \<6 months, unstable angina, uncontrolled hypertension \>160/100 mmHg)
Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation)
Significant neurological impairments that hinder comprehension of instructions or participation in exercise
Terminal illness or conditions limiting life expectancy or ability to complete the study
Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions
Significant orthopedic limitations or injuries that prevent safe exercise participation
Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks
Anticipated or current alcohol consumption \>2 drinks per week, or unwillingness to abstain from alcohol during the study
Current substance abuse affecting study participation or adherence
Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives
Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion
Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results